Although the ADCC response rates to CM235 CRF01_AEinfected cells were similar at the time of and 4 weeks after the third HIV-MVA boost, the magnitude increased significantly (from a median titer of 239 to 578) after the third HIV-MVA vaccination

Although the ADCC response rates to CM235 CRF01_AEinfected cells were similar at the time of and 4 weeks after the third HIV-MVA boost, the magnitude increased significantly (from a median titer of 239 to 578) after the third HIV-MVA vaccination. had IFN- ELISpot responses, 63% to Gag and 42% to Env, 3 years after the second HIV-MVA boost. After the third HIV-MVA, there was an increase in Env-binding antibodies and ADCC-mediating antibodies relative to the response seen at the time of the third HIV-MVA vaccination,p< .0001 andp< .05, respectively. The frequency of IFN- ELISpot responses increased to 95% against Gag or Env and 90% to both Gag and Env,p= .064 andp= .002, respectively. In conclusion, the HIV-DNA prime/HIV-MVA boost regimen elicited potent antibody and cellular immune responses with remarkable durability, and a third HIV-MVA immunization significantly boosted both antibody Glyparamide and cellular immune responses relative to the levels detected at the time of the third HIV-MVA, but not to higher levels than after the second HIV-MVA. Keywords::HIV, vaccine, DNA, MVA, immune response == Introduction == The development of a safeand efficacious preventive HIV vaccine capable of inducing long-lasting humoral and cellular immune responses remains a global health priority.1,2Several HIV vaccine trials at various phases have been conducted worldwide.24Only one phase III trial, RV144, has shown a modest efficacy of 31.2% at 42 months. RV144 evaluated the protective effect of a primeboost regimen consisting of a canarypox-vectored vaccine (ALVAC-HIV vCP1521) and an HIV envelope protein (AIDSVAXB/E) among HIV-uninfected individuals who were at low risk of acquiring HIV infection.5In the analysis of immune correlates of risk of HIV infection in the RV144 trial, it was found that antibodies against the V1/V2 region of HIV-1 Env inversely correlated with the risk of HIV infection, while the presence of IgA Env-binding antibodies was associated with a lack of protection.6Furthermore, antibody-dependent cellular cytotoxicity (ADCC)mediating antibodies and antibodies to the V3 region correlated with reduced risk of HIV infection in vaccinees with low IgA Env binding antibody titers.6,7Analysis of cellular immune responses confirmed the specificity of anti-V2 reactivity.8The efficacy of an HIV vaccine may depend on the longevity of immune responses following vaccination. The parent for the modified vaccinia virus Ankara (MVA) vector, a smallpox vaccine, has the ability to establish long-lived antibody responses.9In RV144, the majority (95%) of vaccinees had binding antibodies to gp120 HIV antigens 2 weeks postfinal vaccination, which waned Glyparamide significantly (to 19%) by 6 months and had reached almost undetectable levels by 28 weeks after the last immunization.10 In our previous HIVIS03 trial, we demonstrated that priming of healthy Tanzanian volunteers with three HIV-DNA and boosting with two HIV-MVA immunizations elicited high levels of neutralizing antibodies (NAb) in up to 83% of vaccinees using a peripheral blood mononuclear cell (PBMC)/Infectious Molecular Clone (IMC) neutralization assay.11However, depletion of natural killer cells from the PBMC targets abrogated the NAb activity, indicating that the neutralizing activity was due to Fc receptormediated antibody functions. ADCC-mediating antibodies were detected in the majority (97%) of the vaccinees 1 month after the second HIV-MVA immunization.12Twenty-eight (97%) of 29 vaccinees exhibited HIV-specific IFN- ELISpot responses, 27 (93%) to Gag and 23 (79%) to Env after the second HIV-MVA vaccination. In the present study, we explored the duration of immune responses and the effect of a third HIV-MVA boost in the HIVIS03 vaccinees 3 years after receipt of three HIV-DNA and two HIV-MVA vaccinations. == Materials and Methods == == Participants == Participants were recruited among volunteers who participated in the previous HIVIS03 trial.11They had previously received three HIV-DNA immunizations at weeks 0, 4, and 12 and two HIV-MVA immunizations at months 9 and 21. The DNA prime included HIV-1 gp160 subtypes A, B, and C; Rev B; Glyparamide Rabbit Polyclonal to PPIF Gag A and B, as well as Glyparamide RTmut B, and the MVA Chiang Mai double recombinant (CMDR, HIV-MVA).